To observe the clinical effect of Xiaoqinglong prescription based on the routine therapy for patients with cold asthma syndrome in acute attack stage of bronchial asthma.Methods：Divided 40 cases of patients with bronchial asthma of cold-asthma type in acute attack stage into the experimental group and the control group randomly，20 cases in each group.Both groups receivedthe routine treatment of western medicine，while the experimental group additionally received Xiaoqinglong prescription orally，and the treatment of both groups lasted for 10 days.Observed the changes of Chinese medicine syndrome scores，levels of programmed cell death 5(PDCD5)and peripheral blood eosinophils as well as indexes of pulmonary function including the percentage of forced expiratory volume in 1 second in the expected value(FEV1%)，the ratio of forced expiratory volume in 1 second to forced vital capacity(FEV1/FVC)，percent predicted forced expiratory flow at 25%(FEF25%)and percent predicted forced expiratory flow at 50%(FEF50%)before and after treatment.Results：After treatment，Chinese medicine syndrome scores and PDCD5 levels in both groups were lower than those before treatment(P ＜0.01)，and Chinese medicine syndrome scores and PDCD5 levels in the experimental group were lower than those in the control group(P＜0.01，P＜0.05).The pulmonary indexes including FEV1%，FEV1/FVC，FEF25%and FEF50%in both groups were respectively higher than those before treatment(P ＜ 0.05，P ＜ 0.01)，and each pulmonary index in the experimental group was higher than that in the control group(P＜0.05)after treatment.Compared the ratios of neutral cells and peripheral blood eosinophils of both groups before and after treatment，no significant difference was found(P ＞ 0.05).Before and after treatment，there was a negative correlation betweenthe expression levels of PDCD5 with FEV1%and FEV1/FVC(P ＜ 0.05，P ＜0.01).Conclusion：PDCD5 involves in the process of airway inflammation，and its abnormal expression may be relevant with uncontrolled asthma，which may become a clinical index or a therapeutic target for assisting in evaluating the control of asthma.Xiaoqinglong prescription can effectively control an asthma attack and improve pulmonary function by regulating the level of PDCD5.